Medicine and device supply issues
This page provides links to information about current supply issues and our instructions to pharmacists.
Benzbromarone (updated 1 May 2020)
Chlorhexidine (HealthE) (updated 6 July 2020)
Clomipramine (added 8 July 2020)
Fluoxetine (updated 28 May 2020)
Gemfibrozil discontinuation (added 25 June 2020)
Labetalol injection (added 17 June 2020)
Levodopa with carbidopa (Sinemet): Resupplied (Updated 20 May 2020)
Montelukast (added 5 June 2020)
Morphine sulphate tablets (discontinuation) (updated 13 May 2020)
Oestradiol (Resupplied 24 June 2020)
Pfizer stock update (updated salazopyrin 25 June 2020)
Prochlorperazine (Buccastem) (added 27 March 2020)
Propofol (updated 12 June 2020)
Ranitidine (Recall) (updated 9 July 2020)
Suxamethonium (updated 6 July 2020)
About stock issues
When PHARMAC is advised that there may be a shortage of a medicine we take measures to ensure that stock is available to New Zealanders.
Many stock shortages do not result in stock running out; deciding when to publicly notify potential impacts to supply is always a judgement call as it may cause an unnecessary run on stock that will result in negative consequences. We work with Medsafe, DHBs, DHB agents, the Pharmacy Guild and other pharmacy-representative groups when deciding what public notice is required and when.
Last updated: 9 July 2020